Century Therapeutics, Inc.: stock overview

IPSCNASDAQHealthcare · Biological Products, (No Diagnostic Substances)

Price

$1.65

November 13, 2026Market cap $297M

DCF calculator

What Ploutos Investor adds for Century Therapeutics

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 4 fiscal years, from 2022
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

In short

Century Therapeutics had revenue of $109M in the fiscal year to December 31, 2025 and a net loss of $99M. Revenue grew by 175.9% a year on average over the last 3 years. It holds more cash than debt, by $117M. It pays no dividend.

From its SEC filings (latest fiscal year to December 31, 2025) and the price of November 13, 2026.

Its SEC filings
Market cap
$297M
180M shares
P/E
–
Revenue, fiscal year
$109M
+175.9% a year over 3 years
Net margin
-8.8%
above 42% of its industry

Worth knowing

What a holder would want to hear from the company's SEC filings of the last three years. Each with its filing, without comment.

3 fiscal years in figures

Each fiscal year's figures as the company filed them, and the share price at its end.

2023–2025 fiscal years

+598.9% a year over 2 years

  • 202510-K
    Revenue$109M
  • 202410-K
    Revenue$6.6M
  • 202310-K
    Revenue$2.2M

Fiscal years in figures

IPSC's revenue, profit, cash flow and dividend with each year-end price, from 2022 to 2022, 1 more fiscal year

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 4 fiscal years.

Key figures

The company's current figures in five groups. Each term is explained behind its ⓘ.

Valuation

Market cap 3-year median: $180M
$297M
Enterprise value 
$179M
P/E 
–
EV / EBIT 
–
EV / Revenue 
1.6
P/B 3-year median: 1.1
1.4
FCF yield 3-year median: -58.3%
–
Earnings yield 3-year median: -69.3%
–

Profitability

Operating margin 
-97.2%
Net margin 3-year median: -1,920.9%
-8.8%
ROIC 
-40.2%
ROIC, 5-year average 
-43.2%
ROE 
-47.4%

Growth

Revenue, yearly change 
+1,556.8%
EPS, yearly change 
–
FCF, yearly change 
–
Revenue, average a year 
+175.9%

The yearly change compares FY2025 with FY2024.

Balance sheet

Cash 
$117M
Total debt 
$37M
Of which operating leases 
$37M
Net cash 
$117M
Net debt / EBITDA 
–
Interest cover 
–
Current ratio 
8.74

Balance sheet of September 30, 2026.

Returns to shareholders

Dividend yield 
0.00%
Buybacks 
–
Total returned 
0.00%
Shares, yearly change 
+108.9%
Valuation against its own pastEach fiscal year's P/E, P/FCF and P/B beside today's, and the DCF calculator for the company.Valuation

Against its industry

Where its margins and returns stood in fiscal 2025 among the SEC filers of its industry (SIC code 28).

Operating margin

-15.8%

Above 37% of the 285 companies in its industry, and 16% of all.

Net margin

-8.8%

Above 42% of the 302 companies in its industry, and 20% of all.

ROE

-6.0%

Above 48% of the 267 companies in its industry, and 22% of all.

ROA

-4.3%

Above 45% of the 313 companies in its industry, and 21% of all.

From the yearly figures every company files with the SEC, for those with revenue of at least $25 million. The industry is the first two digits of the SIC code.

The company at the SEC

How it is registered and when its fiscal year ends.

Name at the SEC
Century Therapeutics, Inc.
CIK
1850119
Exchange
NASDAQ
Industry (SIC)
2836 · Biological Products, (No Diagnostic Substances)
Fiscal year ends
December 31
Latest annual report
December 31, 2025
Reporting currency
USD
Shares
180M

Other companies: Healthcare

The largest companies of the same sector, each with its own page.

The Healthcare sectorAll companies

The full analysis

What do Century Therapeutics's filings show?

These are Century Therapeutics's figures. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

Questions about IPSC

Didn't find what you were looking for?

Ask us
What is IPSC's market cap?

Century Therapeutics, Inc.'s market cap is $297M, at a price of $1.65 on November 13, 2026 and 180M shares.

How much revenue does IPSC have?

Century Therapeutics had revenue of $109M in the fiscal year to December 31, 2025. Over the last 3 years it changed by +175.9% a year on average.

Does IPSC pay a dividend?

No. Century Therapeutics paid no regular dividend over the last 12 months.

Where do the figures come from?

From Century Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and the share price. They hold no analyst estimates and no score, and they are not a recommendation.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

US stocksThe market today, the sectors, the largest companies and the week's results.The market's sectorsThe 11 sectors side by side: returns, share of the market, median P/E and dividend.Compare stocksTwo companies side by side: price over up to ten years, with and without dividends, and every figure.US dividend stocksEach dividend's yield next to whether the company's cash covers it and whether it was ever cut.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.